Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors ; volume:28 ; number:6 ; day:16 ; month:10 ; year:2024 ; pages:821-834 ; date:11.2024
Molecular diagnosis & therapy ; 28, Heft 6 (16.10.2024), 821-834, 11.2024
- Creator
-
Oliveira, Douglas V. N. P.
Biskup, Edyta
O’Rourke, Colm J.
Hentze, Julie L.
Andersen, Jesper B.
Høgdall, Claus
Høgdall, Estrid V.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40291-024-00740-y
- URN
-
urn:nbn:de:101:1-2501162107262.084723466089
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Oliveira, Douglas V. N. P.
- Biskup, Edyta
- O’Rourke, Colm J.
- Hentze, Julie L.
- Andersen, Jesper B.
- Høgdall, Claus
- Høgdall, Estrid V.
- SpringerLink (Online service)
Other Objects (12)
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
High-grade serous ovarian cancer: the clone wars
Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas
A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
High-grade serous ovarian cancer: the clone wars
Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas
A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
High-grade serous ovarian cancer: the clone wars
Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas
A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer